138 related articles for article (PubMed ID: 28902463)
1. Renoprotective effects of montelukast in an experimental model of cisplatin nephrotoxicity in rats.
Gad AM; El-Raouf OMA; El-Sayeh BM; Fawzy HM; Abdallah DM
J Biochem Mol Toxicol; 2017 Dec; 31(12):. PubMed ID: 28902463
[TBL] [Abstract][Full Text] [Related]
2. Ellagic acid antiinflammatory and antiapoptotic potential mediate renoprotection in cisplatin nephrotoxic rats.
El-Garhy AM; Abd El-Raouf OM; El-Sayeh BM; Fawzy HM; Abdallah DM
J Biochem Mol Toxicol; 2014 Oct; 28(10):472-9. PubMed ID: 25044399
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney.
Otunctemur A; Ozbek E; Cekmen M; Cakir SS; Dursun M; Polat EC; Somay A; Ozbay N
Ren Fail; 2013; 35(3):403-10. PubMed ID: 23342977
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Fahmi AN; Shehatou GS; Shebl AM; Salem HA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
[TBL] [Abstract][Full Text] [Related]
5. Influence of montelukast on cisplatin-induced experimental acute renal failure.
Teslariu O; Nechifor M; Plămădeală P; Miron IC
Rev Med Chir Soc Med Nat Iasi; 2014; 118(3):612-7. PubMed ID: 25341273
[TBL] [Abstract][Full Text] [Related]
6. Cysteinyl leukotrienes predominantly mediate cisplatin-induced acute renal damage in male rats.
Hashim AA; Helmy MM; Mouneir SM
J Physiol Pharmacol; 2018 Oct; 69(5):. PubMed ID: 30683829
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats.
Abdel-Raheem IT; Khedr NF
Naunyn Schmiedebergs Arch Pharmacol; 2014 Apr; 387(4):341-53. PubMed ID: 24363042
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of montelukast against cisplatin-induced acute renal damage in rats.
Beytur A; Köse E; Sarihan ME; Sapmaz HI; Dogan Z; Cetin A; Vardi N; Turkoz Y; Ekinci N
Ren Fail; 2012; 34(3):343-9. PubMed ID: 22260262
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats.
Otunctemur A; Ozbek E; Cakir SS; Dursun M; Cekmen M; Polat EC; Ozcan L; Somay A; Ozbay N
Int Braz J Urol; 2015; 41(2):279-87. PubMed ID: 26005969
[TBL] [Abstract][Full Text] [Related]
10. Montelukast ameliorates kidney function and urinary bladder sensitivity in experimentally induced renal dysfunction in rats.
Suddek GM
Fundam Clin Pharmacol; 2013 Apr; 27(2):186-91. PubMed ID: 21985664
[TBL] [Abstract][Full Text] [Related]
11. Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats.
Helmy MM; Helmy MW; Abd Allah DM; Abo Zaid AM; Mohy El-Din MM
Eur J Pharmacol; 2014 May; 730():133-9. PubMed ID: 24632086
[TBL] [Abstract][Full Text] [Related]
12. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
[No Abstract] [Full Text] [Related]
13. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.
Erşahin M; Çevik Ö; Akakın D; Şener A; Özbay L; Yegen BC; Şener G
Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):131-9. PubMed ID: 22986158
[TBL] [Abstract][Full Text] [Related]
14. Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production.
Helmy MM; El-Gowelli HM
Eur J Pharmacol; 2012 May; 683(1-3):294-300. PubMed ID: 22449377
[TBL] [Abstract][Full Text] [Related]
15. Montelukast protects against renal ischemia/reperfusion injury in rats.
Sener G; Sehirli O; Velioğlu-Oğünç A; Cetinel S; Gedik N; Caner M; Sakarcan A; Yeğen BC
Pharmacol Res; 2006 Jul; 54(1):65-71. PubMed ID: 16584888
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers.
Sherif IO; Al-Mutabagani LA; Alnakhli AM; Sobh MA; Mohammed HE
Exp Biol Med (Maywood); 2015 Dec; 240(12):1572-9. PubMed ID: 25825359
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of melatonin versus montelukast in cisplatin-induced seminiferous tubule damage in rats.
El-Shafaei A; Abdelmaksoud R; Elshorbagy A; Zahran N; Elabd R
Andrologia; 2018 Nov; 50(9):e13077. PubMed ID: 30019386
[TBL] [Abstract][Full Text] [Related]
18. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of α2C-adrenoceptors ameliorates cisplatin-induced acute renal failure in rats.
Tsutsui H; Shimokawa T; Miura T; Takama M; Nishinaka T; Terada T; Yamagata M; Yukimura T
Eur J Pharmacol; 2018 Nov; 838():113-119. PubMed ID: 30201375
[TBL] [Abstract][Full Text] [Related]
20. Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats.
Ibrahim MA; Amin EF; Ibrahim SA; Abdelzaher WY; Abdelrahman AM
Eur J Pharmacol; 2014 Feb; 724():204-10. PubMed ID: 24370493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
